Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Debuts: Spinal Innovation From NuVasive, Life Spine; Teleflex Targets EuroPCR For Arrow AC3 Optimus; Abiomed Pushes 3-G Impella

Executive Summary

This edition of Device Debuts covers the innovative devices introduced into commercial markets since the mid-April, typically a busy time for product launches as it coincides with spring's big medical meetings. This includes a series of spine-surgery technologies showcased at the AANS meeting and devices that support blood circulation during interventions that were featured at EuroPCR and SCAI.

You may also be interested in...



Teleflex Buys Vascular Solutions For $1bn To Improve Growth

The purchase price of $56 a share in cash is a modest 16% premium over Vascular Solutions' 90-day average price. Vascular Solutions' CEO says uncertainty about the future leadership of the company compelled it to consider acquisition offers.

US FDA Approves Abiomed’s Impella For Cardiogenic Shock Ahead Of Schedule

US FDA has approved earlier than anticipated Abiomed’s Impella 2.5, Impella CP, Impella 5.0 and Impella LD transcatheter ventricular assist devices to provide treatment of ongoing cardiogenic shock.

Varian Launches Trial Of Flash Ultra-High Dose Radiotherapy

The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel